A prospective non-randomized trial: the use of platinum-containing chemotherapy with mitomycin for relapses of BRCA1-associated ovarian cancer


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. BRCA1-associated ovarian cancer (OC) demonstrates a high sensitivity to DNA-damaging agents, but the most effective drug regimen for disease recurrence has not been determined. Objective. Evaluation of the efficacy of platinum-containing chemotherapy with mitomycin for the recurrence of OC with BRCA1 gene mutation. Methods. The study included 12 patients with relapse of a BRCA-associated OC who were treated in the N.N. Petrov NMRCO of the Ministry of Health of the Russian Federation from 2015 to 2017. Mitomycin (10 mg/m2) and cisplatin (100 mg/m2) or carboplatin (AUC6) preparations were administered intravenously every 3-4 weeks. Results. Complete clinical regression was recorded in 5/12 (41.67%) patients, partial regression - in 5/12 (41.67%), stabilization of the disease - in 2/12 (16.67%). A decrease in Ca-125 level was observed in all patients during treatment. Median progression-free survival was 11.5 months. Grade 3-4 toxicity, according to NCI CTC criteria, was detected in 4/12 (33.33%) patients. Conclusion The results of the trial can serve as a basis for planning a randomized study on the efficacy and toxicity of combined platinum-containing chemotherapy with mitomycin for relapses of BRCA1-associated OC.

Full Text

Restricted Access

About the authors

Kh. B Kotiv

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University named after I.I. Mechnikov

Email: Kotiv.onc@gmail.com
PhD, Researcher at the Research Department of Oncogynecology 68, Leningradskaya Street, Pesochny settlement, St. Petersburg 197758, Russian Federation

M. G Yakovleva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. P Sokolenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

T. V Gorodnova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. O Ivantsov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

E. A Nekrasova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

O. A Smirnova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. A Sidoruk

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University named after I.I. Mechnikov

St. Petersburg, Russia

N. E Bondarev

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

I. E Meshkova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

N. A Mikaya

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

S. V Petrik

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. F Urmancheeva

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University named after I.I. Mechnikov

St. Petersburg, Russia

E. A Ulrikh

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University named after I.I. Mechnikov

St. Petersburg, Russia

S. A Protsenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. M Belyaev

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University named after I.I. Mechnikov

St. Petersburg, Russia

E. N Imyanitov

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University named after I.I. Mechnikov

St. Petersburg, Russia

I. V Berlev

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University named after I.I. Mechnikov

St. Petersburg, Russia

References

  1. Горбунова А.В. Повторные циторедуктивные операции и вторая линия химиотерапии при лечении рецидивов рака яичников. Дисс. канд. мед. наук. М., 2001. C. 132-50
  2. Портнова Н.И. Выявляемость злокачественных опухолей яичников в условиях диспансеризации и причины смерти больных. Дис. канд. мед. наук. 2001. 147 с
  3. Armstrong D.K. Relapsed ovarian cancer: Challenges and management strategies for a chronoic disease. Oncologist. 2002;7(5):20-28.
  4. Alsop K, Fereday S., Meldrum C., et al. BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654-63. Doi: 10.1200/ JCO.2011.39.8545.
  5. Kaye S.B., Lubinski J., Matulonis U., et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib,a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30(4):372-79. doi: 10.1200/JCO.2011.36.9215.
  6. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. J Clin Oncol. 2014;32(13):1302-308. doi: 10.1200/JCO.2013.51.4489.
  7. Tan D.S.P, Kaye S.B. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different? Am Soc Clin Oncol. Educ. B. 2015;35:114-21. doi: 10.14694/EdBook_ AM.2015.35.114.
  8. Stordal B., Davey R. A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: Role of BRCA1. Curr Cancer Drug Targets. Bentham Science. 2009;9(3):354-65.
  9. Sung M, Giannakakou Ft BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling. Oncogene. 2014;33(11):1418-28. Doi: 10.1038/ onc.2013.85.
  10. Hollis R.L., Churchman M, Gourley C. Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. Onco Targets Ther Dove Press. 2017;10:2539-51. doi: 10.2147/OTT.S102569.
  11. Leunen K., Cadron I., Van Gorp T, et. al. Does Paclitaxel-Carboplatin Chemotherapy in a Dose-Dense Regimen Enhance Survival of BRCA-Related Ovarian Cancer Patients? Int J Gynecol Cancer. 2009;19:(9):1501-504. Doi: 10.1111/ IGC.0b013e3181bb703f.
  12. Tan D.S., Yap T.A., Hutka M., et al. Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. Eur J Cancer. 2013;49(6):1246-53. doi: 10.1016/j.ejca.2012.11.016.
  13. Samou§lian V, Maugard C.M., Jolicoeur M., et al. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGF?-RII, KRAS2, TP53 and/or CDNK2A. Cancer Chemother Pharmacol. 2004;54(6): 497-504.
  14. Tagliaferri P, Ventura M., Baudi F., et al. BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality? J Ovarian Res BioMed Central. 2009;2:14. doi: 10.1186/1757-2215-2-14.
  15. Safra T., Rogowski O., Muggia F.M. The Effect of Germ-Line BRCA Mutations on Response to Chemotherapy and Outcome of Recurrent Ovarian Cancer. Int J Gynecol Cancer. 2014;24(3):488-95. doi: 10.1097/IGC.0000000000000086.
  16. Hyman D.M., Zhou Q., Arnold A.G., et al. Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol. NIH Public Access. 2011;123(2):196-99. doi: 10.1016/j.ygyno.2011.07.019.
  17. Thorn C.F, Oshiro C., Marsh S., et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. NIH Public Access. 2011;21(7):440-46. Doi: 10.1097/ FPC.0b013e32833ffb56.
  18. Mantia-Smaldone G., Ronner L., Blair A., et al. The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1- deficient ovarian tumors and can be exploited to improve treatment response in a mouse model. Gynecol Oncol. 2014;133(3):584-90. Doi: 10.1016/j. ygyno.2014.03.565.
  19. Moiseyenko V.M., Chubenko V.A., Moiseyenko F.V., et al. Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation. Med Oncol. Springer US. 2014;31(10):199. doi: 10.1007/s12032-014-0199-x.
  20. Gorodnova T.V, Kotiv K.B., Ivantsov A.O., et al. Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer. Int J Gynecol Cancer. 2018;28(8):1498-1506. doi: 10.1097/IGC.0000000000001352.
  21. Городнова Т.В., Соколенко А.П., Иванцов А.О., и др. Системная терапия распространенного рака яичников у носительниц мутаций в гене BRCA1 - новые лечебные подходы: результаты проспективного нерандомизированного многоцентрового исследования. Фарматека. 2018;7:57-64.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media